Specialty pharmaceutical and medical device company FSC Laboratories has licensed a seasonal allergy drug from New Jersey company Tris Pharma.

FSC, based in Charlotte, said that it expects Karbinal ER will be available in U.S. pharmacies in time for the 2014 spring allergy season. The drug, an oral suspension, is approved for use in children as young as two years old. Tris received Food and Drug Administration approval on Karbinal ER in April.

Under the terms of the agreement, Tris will manufacture Karbinal ER using its proprietary technology. FSC will market the drug. FSC will pay Tris up to $20 million in milestones, dependent on sales of the drug. FSC will also pay Tris Pharma a double-digit royalty on net sales.